论文信息 - Somatic Reversion of Germline BRCA2 Mutation Confers Resistance to Poly(ADP-ribose) Polymerase Inhibitor Therapy. - 字舞流文

Somatic Reversion of Germline BRCA2 Mutation Confers Resistance to Poly(ADP-ribose) Polymerase Inhibitor Therapy.

E. Swisher | David Wu | C. Pritchard | V. Gadi | K. Banda

[1] Alan Ashworth,et al. Mechanisms of resistance to therapies targeting BRCA-mutant cancers , 2013, Nature Medicine.

[2] A. Ashworth,et al. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor , 2013, The Journal of pathology.

[3] Rochelle L. Garcia,et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4] E. Swisher,et al. Secondary mutations of BRCA1/2 and drug resistance , 2011, Cancer science.

[5] T. Walsh,et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing , 2010, Proceedings of the National Academy of Sciences.

[6] Jorge S. Reis-Filho,et al. Resistance to therapy caused by intragenic deletion in BRCA2 , 2008, Nature.

[7] F. Couch,et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers , 2008, Nature.

[8] Renato Martins,et al. Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. , 2014, The Journal of molecular diagnostics : JMD.